Increased expression of the transmembrane P-glycoprotein is a major cause of the phenomenon of multidrug resistance that is observed in the treatment of many cancers (1) . P-glycoprotein (p170 mdr-1 ) is an integral membrane protein of 170 kd in size that is encoded by the human mdr-1 gene (also named PGY1) (2) . It functions as an energy-dependent drug-efflux pump to reduce drug accumulation and can therefore confer resistance to a variety of chemotherapeutic agents (3, 4) . The Pglycoprotein is expressed in many different types of normal human tissues and tumors (5) (6) (7) . Several antibodies raised against P-glycoprotein are available for use in the detection of p170 mdr-1 , of which the monoclonal antibody C219 is by far the most widely used in the clinic and laboratory (7) (8) (9) . Elevated expression of P-glycoprotein has also been associated with both the invasiveness and the metastatic ability of tumor cells (10) . Thus, P-glycoprotein overexpression in tumor cells may both confer resistance to certain antineoplastic drugs and facilitate their dissemination (7) .
The c-erbB2 gene (also named HER-2, neu, or NGL) encodes a transmembrane glycoprotein of 185 kd (p185 c-erbB2 ) that has extensive sequence homology with the epidermal growth factor receptor and has intrinsic tyrosine kinase activity (11) (12) (13) (14) (15) . Amplification and/or overexpression of the c-erbB2 gene was found in about 30% of human breast carcinoma specimens and was positively associated with lower overall survival rate, shorter time to relapse, and lymph node metastasis in breast cancer patients (16) (17) (18) . In recent studies (19, 20) , we demonstrated that overexpression of p185 c-erbB2 in c-erbB2 gene-transfected MDA-MB-435 human breast cancer cells (435.eB transfectants) can enhance both their metastatic potential and their intrinsic chemoresistance to paclitaxel. These observations provided reasonable explanations for the reported clinical association between overexpression of p185 c-erbB2 and poor clinical outcome of breast cancer patients. In addition, these observations demonstrated that overexpression of p185 c-erbB2 in breast cancer cells may result in biologic consequences similar to those of overexpression of p170 mdr-1 (i.e., drug resistance and metastasis).
A statistically significant (P ‫ס‬ .009; two-sided Fisher's exact test) association was found between c-erbB2 and mdr-1 expression in the more aggressive form of locally advanced mammary carcinoma (21) . This association suggested that the mdr-1 and c-erbB2 genes might be regulated by a common mechanism (22) . In addition, the common biologic consequences of c-erbB2 and mdr-1 gene overexpression raised an important question: Is p170 mdr-1 involved in increased resistance of p185-overexpressing 435.eB transfectants to paclitaxel? In pursuing this issue, we found that p170 mdr-1 does not contribute to the increased resistance of 435.eB transfectants to paclitaxel (20) . It is interesting that we have unexpectedly discovered that anti-p170 mdr-1 monoclonal antibody C219 can cross-react with p185 c-erbB2 . In this report, we provide detailed evidence regarding C219 crossreactivity with p185 c-erbB2 . (20) . All transfectants were grown under the same conditions as the MDA-MB-435 cells except that the neomycin analogue G418 (800 g/mL) was added to the culture medium.
Materials and Methods
Immunoprecipitation and immunoblotting. Whole-cell extracts were prepared by lysing 3 × 10 6 cells with the immunoprecipitation buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris [pH 7.4], 1 mM ethylene glycol-bis-tetraacetic acid, 0.2 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5% Nonidet P-40). Protein concentrations of the cell extracts were determined with a protein assay kit (Pierce Chemical Co., Rockford, IL). Equal amounts of protein from each sample were incubated with 1 g/mL of c-neu-Ab3 monoclonal antibody against p185 c-erbB2 (Oncogene Science, Inc., Uniondale, NY) for 2 hours at 4°C; after addition of protein A-agarose (Boehringer Mannheim Corp., Indianapolis, IN), incubation continued for another 1 hour at 4°C. The immunoprecipitates were washed three times with the immunoprecipitation buffer and resuspended in sodium dodecyl sulfate (SDS) sample buffer. Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose (Bio-Rad Laboratories, Hercules, CA). Immunoblotting was then performed as described previously (23) . The primary antibodies used were monoclonal antibody c-neuAb3 against the c-erbB2-encoded p185, polyclonal antibody mdr-1-Ab1 against mdr-1-encoded Pglycoprotein (Oncogene Science, Inc.), and monoclonal antibody C219 against P-glycoprotein (Signet Laboratories, Inc., Dedham, MA). The blots were then incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (Bio-Rad Laboratories). Proteins were detected by enhanced chemiluminescence (Amersham Corp., Arlington Heights, IL).
Immunohistochemical analysis. For immunohistochemical detection of the p170 mdr-1 and p185 c-erbB2 in breast cancer cell lines, an avidinbiotinyl peroxidase technique was used (24) . In brief, slides of breast cancer cell lines were obtained by cytospin (1000 rpm, 1 minute at room temperature) and fixed in 100% cold acetone (Sigma Chemical Co., St. Louis, MO) for 10 minutes at room temperature. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide in methanol for 15 minutes at room temperature. The slides were preincubated with 1% normal horse serum (Vector Laboratories, Inc., Burlingame, CA) in phosphate-buffered saline (PBS). They were then incubated overnight at 4°C with one of the following antibodies diluted in PBS: anti-p170 mdr-1 rabbit polyclonal antibody (1:10), anti-p170 mdr-1 monoclonal antibody C219 (1:5), and c-neu-Ab3 antip185 c-erbB2 monoclonal antibody (1:1600). The slides were washed extensively with PBS and were incubated at room temperature for 60 minutes with secondary biotinylated antibodies (diluted 1:200 in PBS); goat anti-rabbit immunoglobulin G (IgG) was used for the polyclonal antibodies, and goat antimouse IgG was used for the monoclonal antibodies (Vector Laboratories, Inc.). The slides were then incubated for 1 hour at room temperature with avidinbiotinyl peroxidase complex (Vector Laboratories, Inc.), the complex was diluted 1:100 in PBS, and the peroxidase was visualized with 0.125% amino-ethyl carbazole chromogen substrate solution (Sigma Chemical Co.). After light counterstaining with Mayer's hematoxylin (Sigma Chemical Co.), the slides were mounted and photographed. We used 1% normal horse serum (Vector Laboratories, Inc.) to replace the primary antibody as negative controls in each staining.
Sequence alignment. We analyzed the peptide sequence homology between p185 c-erbB2 and p170 mdr-1 by using the program of the Wisconsin Sequence Analysis Package (Genetic Computer Group, Madison, WI).
Peptide enzyme-linked immunosorbent assays (ELISAs). Aliquots containing 2 g of each peptide in 100 L of PBS were denatured by boiling, then coated on ELISA plates (Corning Laboratory Science Co., Corning, NY) at 4°C overnight. C219 (2 g/mL) was added to the peptide-coated 96-well plates and incubated for 3 hours at room temperature. After biotinylated secondary goat anti-mouse IgG (Vector Laboratories, Inc.) was added to the plates for 1 hour, 100 L of avidin-biotin complex (VECTASTAIN ABC Reagent; Vector Laboratories, Inc.) was added for another 30 minutes. Binding of the monoclonal antibody C219 to each peptide was detected by use of the AEC Substrate Kit (Vector Laboratories, Inc.), which yielded red crystals. After the supernatant was removed, 100 L of dimethyl sulfoxide (Fisher Scientific Co., Fairlawn, NJ) was added to each well to dissolve the crystals; the plates were then read by a microplate reader (Molecular Devices Corp., Menlo Park, CA) at a wavelength of 490 nm.
Results

High Levels of p170 mdr-1 in 435.eB Transfectants Measured by Use of Monoclonal Antibody C219
We recently found that overexpression of p185 c-erbB2 in human breast cancer cells confers increased cellular resistance to paclitaxel (20) . Among the MDA-MB-435 transfectants, the 435.neo.1 cells expressed p185 c-erbB2 protein (determined by western blot analysis) at levels similar to those of the MDA-MB-435 parental cells and were as sensitive to paclitaxel as the MDA-MB-435 cells (20) . The 435.eB1, 435.eB2, 435.eB3, and 435.eB4 cells expressed p185 c-erbB2 protein at levels 258-, 149-, 135-, and 165-fold higher, respectively, than those of the parental MDA-MB-435 cells, and they were fourfold to ninefold more resistant to paclitaxel than the MDA-MB-435 cells (20) . Similar p170 mdr-1 levels were observed among the p185-low-expressing cells and the p185-overexpressing 435.eB transfectants by western blotting by use of an anti-p170 mdr-1 polyclonal antibody (20) . In the current study, increased levels of a protein of approximately 170-185 kd were detected in the p185-overexpressing 435.eB transfectants when western blot analysis was performed with the use of the anti-p170 mdr-1 monoclonal antibody C219 (Fig. 1) , whereas the control 435.neo.1 cells had levels of the 170-to 185-kd protein similar to those of the parental MDA-MB-435 cells (Fig. 1) . Thus, western blot analysis by use of two different anti-p170 mdr-1 antibodies resulted in apparently contradictory findings.
However, our previous study (20) demonstrated that the paclitaxel resistance of 435.eB transfectants was not reversed by thioridazine, which blocks p170 mdr-1 function. Therefore, mdr-1 did not contribute to the paclitaxel resistance of the 435.eB transfectants (20) . It is interesting that the 170-to 185-kd protein levels detected by western blotting with the use of C219 corresponded to p185 c-erbB2 expression levels in the 435.eB1, 435.eB2, 435.eB3, and 435.eB4 cells [ Fig. 1; (20) ], which suggested that C219 may cross-react with p185 c-erbB2 .
Cross-reactivity of C219 With p185 c-erbB2
To test whether C219 may cross-react with p185
c-erbB2 , we performed immunoprecipitation-western blot analysis using the 435.eB transfectants that overexpressed p185 c-erbB2 but showed contradictory p170 mdr-1 levels upon western blotting with two different antibodies. The parental MDA-MB-435 cells that express both p185 c-erbB2 and p170 mdr-1 at low levels were used as negative controls. Protein lysates from MDA-MB-435, 435.eB1, and 435.eB4 cells were first immunoprecipitated with the c-neu-Ab3 antip185 c-erbB2 . Immunoprecipitates of each cell line were divided into three equal parts, separated by SDS-PAGE along with protein lysates of SKBR-3 breast cancer cells that overexpress both p185 c-erbB2 and p170 mdr-1 , and were used as positive controls (20) . Western blot analyses were then performed with the use of the following three antibodies: c-neu-Ab3 antip185 c-erbB2 (Fig. 2, A) , the polyclonal antibody mdr-1-Ab1 against p170 mdr-1 (Fig.  2, B) , and the monoclonal antibody C219 anti-p170 mdr-1 (Fig. 2, C) . Western blotting with the use of the c-neu-Ab3 against p185 c-erbB2 demonstrated p185 overexpression in the 435.eB1 and 435.eB4 transfectants that comigrated with the p185 protein from the lysates of p185-overexpressing SKBR-3 cells (Fig. 2, A) .
The results were consistent with our previous observation (20) and indicated that p185 had been efficiently immunoprecipitated by the c-neu-Ab3 antibody. As predicted, western blotting with the use of the anti-p170 mdr-1 polyclonal antibody mdr-1-Ab1 demonstrated a strong p170 mdr-1 band in the lysates of SKBR-3 cells that overexpress p170 mdr-1 . No p170 mdr-1 signals were detected, however, from any immunoprecipitate of the three cell lines by western blotting with the use of the same anti-p170 mdr-1 polyclonal antibody (Fig. 2, B) . The fact that no p170 mdr-1 was found in the immunoprecipitates indicated that c-neu-Ab3 cannot recognize p170 mdr-1 and p170 mdr-1 does not associate with p185 c-erbB2 . Protein bands of approximately 170-185 kd were detected in the immunoprecipitates of 435.eB1 and 435.eB4 transfectants, but not in the immunoprecipitates of MDA-MB-435 cells, by western blotting with the use of monoclonal antibody C219 (Fig. 2, C) . Although the signals from the C219 western blot were generally weaker than those from the c-neu-Ab3 western blot, higher levels of p185 c-erbB2 in 435.eB1 cells in the c-neu-Ab3 western blot corresponded to a stronger signal in the C219 western blot (compare Fig. 2, A, with Fig. 2, C) . Moreover, C219 western blot of the lysates from SKBR-3 cells that overexpress both p170 mdr-1 and p185 c-erbB2 demonstrated a p185 band (labeled with asterisk in Fig. 2, C, last lane) . This p185 band comigrated with the 170-to 185-kd signals in the anti-p185 c-erbB2
immunoprecipitates of 435.eB1 and 435.eB4 transfectants in addition to the p170 mdr-1 band (labeled with an arrowhead, Fig. 2 , C, last lane). The results indicated that the anti-p170 mdr-1 monoclonal antibody C219 can cross-react with denatured p185 c-erbB2 in western blotting. To further confirm our observation on the cross-reactivity of monoclonal antibody C219 with p185 c-erbB2 and to determine whether C219 may cross-react with p185 c-erbB2 when used in immunohistochemical staining, we prepared slides of SKBR-3, 435.eB1, and MDA-MB-435 cells by cytospin for immunohistochemical analysis (Fig. 3, A) . The SKBR-3 cells used as the positive control (Fig. 3, A , left panels) demonstrated strong positive staining of p185 by use of c-neu-Ab3 (Fig. 3, A, left panel, top) , strong signals of p170 mdr-1 staining by use of the polyclonal mdr-1-Ab1 (Fig. 3, A, left panel,  middle) , and clear positive p170 mdr-1 signals by use of monoclonal antibody C219 (Fig. 3, A, left panel, bottom) . In contrast, the MDA-MB-435 cells (Fig. 3, A , right panels) expressed very low levels of p185 c-erbB2 and p170 mdr-1 and, as expected, were negative for immunohistochemical staining with all three antibodies. For the 435.eB1 transfectants (Fig. 3 , A, middle panels) that expressed high levels of p185 c-erbB2 (top) but extremely low levels of p170 mdr-1 (20) , reactivity with the anti-p170 mdr-1 polyclonal antibody was negative (Fig. 3, A, middle panel,  middle) , as it was for MDA-MB-435 cells, but reactivity with the monoclonal antibody C219 was positive (Fig. 3, A,  middle panel, bottom) . The results demonstrated that monoclonal antibody C219 can cross-react with p185 c-erbB2 in immunohistochemical staining.
To quantify the degree of crossreactivity of the monoclonal antibody C219 with p185 c-erbB2 , the C219 signals in the immunohistochemically stained slides of SKBR-3, 435.eB1, and MDA-MB-435 cells were scanned with the Imaging Analyzer SAMBA 4000 (Imaging Products International, Inc., Chantilly, VA) (Fig. 3, B) . When we compared the signal intensities of C219 staining among the three cell lines by determining mean optical density, the 435.eB cells demonstrated a more intense signal than the MDA-MB-435 cells (Fig. 3, B) , although both cell lines had similar p170 mdr-1 expression levels. Again, reactivity with C219 corresponded to the p185 c-erbB2 expression level, a finding that is consistent with the western blot results described above.
Recognition by C219 of an Epitope in p170 mdr-1 That Shares Homology With p185 c-erbB2
To further determine the molecular basis of C219 cross-reactivity with p185 c-erbB2 , we investigated the possibility that p185 c-erbB2 may contain the epitope recognized by monoclonal antibody C219. Amino acid sequence analyses of p185 c-erbB2 revealed that a seven-aminoacid peptide (VVQGNLE) in p185 c-erbB2
(11) shares sequence homology with monoclonal antibody C219 epitope (VVQVALD) in p170 mdr-1 (8) (Fig. 4, A) . The most critical amino acid residues in the VVQVALD epitope for C219 recognition are the second valine (V), the sixth leucine (L), and the seventh aspartate (D), since peptide ELISA demonstrated that removal of the second valine abolished C219 binding, whereas addition of the sixth leucine or seventh aspartate enhanced C219 binding to the epitope (8) . Although the peptide sequence in p185 c-erbB2 does not match completely the C219 epitope, two of these three critical amino acids are identical (second valine and sixth leucine) between p170 mdr-1 and p185 c-erbB2 . The other critical amino acid in the C219 epitope, the seventh amino acid aspartate (D), shares similar structure and biochemical properties with glutamate (E) in the VVQGNLE sequence in p185 c-erbB2 . It is possible, therefore, that C219 may recognize the homologous VVQGNLE peptide in p185 c-erbB2 . To investigate this possibility directly, we tested the binding capability of monoclonal antibody C219 to the VVQGNLE peptide in p185 c-erbB2 by peptide ELISA. Three peptides (p170 mdr-1 , p185 c-erbB2 , and control peptide), each containing 14 amino acids, were synthesized and coated to ELISA plates as antigens. The p170 mdr-1 peptide (SEAVVQVALD-KARK) includes the seven-amino-acid epitope (underlined) of monoclonal antibody C219 in p170 mdr-1 . The p185 c-erbB2
peptide (GCQVVQGNLELTYL) includes the seven-amino-acid sequence in c-erbB2 that shares homology with the C219 epitope. In the control peptide (GCQKKLGNRFLTYL), the seven homologous amino acids in the p185 c-erbB2
were replaced by irrelevant amino acids, but their flanking amino acids were identical to those of the p185 c-erbB2 peptide. C219 did indeed bind to the p185 c-erbB2 peptide as well as to the p170 mdr-1 peptide, but not to the control peptide (Fig. 4, B) . The results confirmed that C219 can recognize the VVQGNLE sequence in the p185 c-erbB2 peptide that is homologous to that of the C219 epitope in p170 mdr-1 .
Discussion
In both immunoprecipitationwestern blotting and immunohistochemical staining studies, we found that monoclonal antibody C219 can crossreact with p185 c-erbB2 (Figs. 2, 3) . In addition, we demonstrated that C219 recognizes a seven-amino-acid peptide, VVQGNLE, in p185 c-erbB2 that shares sequence homology with the C219 epitope (VVQVALD) in p170 mdr-1 (8) . Comparison between the two peptides revealed that four of the amino acids are identical, two have similar properties, and only one amino acid is different (Fig. 4, A) (25) and monoclonal antibody JSB-1 (26) were used. Therefore, cross-reactivity of C219 with p185 c-erbB2 may not be a serious issue in their study. In addition, although both the SKBR-3 breast cancer cells and the 435.eB1 transfectants used in this study express p185 c-erbB2 at levels routinely found in primary human breast cancers (20, 27) , C219 cross-reactivity with p185 c-erbB2 may be less problematic in heterogeneous tumor biopsy specimens than in homogeneous cell lines. It is possible that C219 cross-reactivity with p185 c-erbB2 may be observed only in breast tumors that express very high levels of p185 c-erbB2 . Nevertheless, the crossreactivity of C219 with p185 c-erbB2 calls for caution in the interpretation of previous data regarding p170 mdr-1 expression in tumor specimens as determined by use of C219.
Although overexpression of p170 mdr-1 and overexpression of p185 c-erbB2 both have been shown to contribute to cancer chemoresistance and to tumor invasiveness and metastasis (10, 20, 28, 29) , p170 mdr-1 and p185 c-erbB2 have other distinct functions and mechanisms involved in human cancer. It is vitally important to accurately distinguish p170 mdr-1 overexpression and/or p185 c-erbB2 overexpression in breast cancer specimens, since p170 mdr-1 and p185 c-erbB2 are frequently used in determining prognosis and treatment responses in breast cancer patients.
C219 has a high affinity for mouse and hamster P-glycoprotein and can react with all P-glycoprotein isoforms (8); it is not species specific and can recognize human p170 mdr-1 with lower affinity (30) . The antibody recognizes a small, highly conserved, c-terminal intracellular epitope located close to the adenosine triphosphatebinding site of the P-glycoprotein (8). C219 may cross-react with cardiac muscle myosin heavy chain (5, 31) and an unknown protein of 190 kd in size that is present in brain capillaries (32) . The unknown 190-kd protein is unlikely to be p185 c-erbB2 , since the 190-kd protein is completely insoluble in Triton X-114 (32), whereas p185 c-erbB2 can be extracted by Triton X-114 (data not shown).
Although cross-reactivity of C219 with these other distinct proteins has been reported, our new findings that C219 can cross-react with p185 c-erbB2 have an even more substantial impact on studies regarding expression of p170 mdr-1 and p185 c-erbB2 in human cancers. Our findings will have important implications in both laboratory and clinical studies.
First, overexpression of p185 c-erbB2 has been found in approximately 30% of human primary breast cancers and in a substantial portion of many other human cancer types (16) (17) (18) 33) . Our immunohistochemical data suggest that C219 may yield false-positive results in these . A) Amino acid sequence analysis of p185 c-erbB2 indicated that a sevenamino-acid peptide (VVQGNLE) in the p185 c-erbB2 protein shares sequence homology with the C219 epitope in p170 mdr-1 (VVQVALD, indicated with numbers 1-7). B) Peptide enzyme-linked immunosorbent assay demonstrated that monoclonal antibody C219 can bind to the peptide containing the p170 mdr-1 epitope (left) and the peptide containing the seven homologous amino acids in the p185 c-erbB2 (middle) but not to the control peptide (right). p185 c-erbB2 -overexpressing tumor specimens because the positive signal of C219 may actually be due to cross-reactivity with the overexpressed p185 c-erbB2 in these tumor specimens. Second, among the various antibodies available to detect p170 mdr-1 , C219 is by far the most extensively characterized and has been the most frequently used antibody for immunohistochemical screening of p170 mdr-1 expression in normal and tumor tissues (7) . The cross-reactivity of C219 with p185 c-erbB2 described in this report attests to the need for more careful interpretation of the results obtained by use of monoclonal antibody C219. We conclude that it is critical to use more than one antibody to assess p170 mdr-1 expression in cancer cell lines and tumor tissues, especially in tumors that overexpress p185 c-erbB2 , to prevent inaccurate future results.
